14 completed, 7 terminated, 3 recruiting, 3 unknown. 11 Phase 3, 8 Phase 2, 6 Phase 4, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Completed 7, Recruiting 2, Terminated 2 |
| Phase 2 | 8 | Terminated 3, Completed 2, Unknown 2, Active not recruiting 1 |
| Phase 4 | 6 | Completed 4, Terminated 2 |
| Phase 1 | 1 | Unknown 1 |
Follow Ferrer Internacional S.A.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pridopidine Phase 3 Study in Huntington's Disease Pridopidine, Placebo - Huntington Disease | Phase 3 | Recruiting | Prilenia | 400 | 2026-07-01 | 2026-10-28 |
| Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS Pridopidine, Placebo - Amyotrophic Lateral Sclerosis | Phase 3 | Recruiting | Prilenia | 500 | 2026-02-01 | 2026-10-27 |
| Treprostinil in Newborns With Pulmonary Hypertension; a Non-Interventional Study to Collect Data on Drug Utilization, Safety, and Effectiveness Persistent Pulmonary Hypertension of Newborn | Recruiting | Ferrer Internacional S.A. | 60 | 2025-02-25 | 2025-09-03 | |
| A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP) FNP-223, Placebo - Progressive Supranuclear Palsy | Phase 2 | Active not recruiting | Ferrer Internacional S.A. | 241 | 2024-07-23 | 2025-10-15 |
| Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis FAB122 - Amyotrophic Lateral Sclerosis | Phase 3 | Terminated | Ferrer Internacional S.A. | 201 | 2023-03-06 | 2025-03-04 |
| Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis FAB122, Placebo - Amyotrophic Lateral Sclerosis | Phase 3 | Completed | Ferrer Internacional S.A. | 313 | 2021-10-18 | 2025-03-18 |
| Cangrelor in Patients With Acute Myocardial Infarction Undergoing PCI After CPR, Ventilated or Cardiogenic Shock Acute Myocardial Infarction | Completed | IHF GmbH - Institut für Herzinfarktforschung | 303 | 2021-05-04 | 2022-07-27 | |
| Clinical Trial in Children Between 3 Months and 14 Years Old to Evaluate the Efficacy and Safety of Gelatin Tannate in the Treatment of Acute Diarrhea (INDIGO) Gelatin tannate (GT) + oral rehydration solution (ORS) + Zinc supplementation, placebo + ORS + Zinc supplementation - Diarrhea | Phase 3 | Completed | Ferrer Internacional S.A. | 150 | 2019-09-11 | 2020-11-04 |
| Safety and Preliminary Efficacy of FAB117-HC in Patients With Acute Traumatic Spinal Cord Injury FAB117-HC, Control group - Acute Traumatic Spinal Cord Injury | Phase 1 / Phase 2 | Unknown | Ferrer Internacional S.A. | 48 | 2016-12-01 | 2021-09-16 |
| Phase IV to Evaluate the Safety of Self-administered ADASUVE® in Agitated Patients Outside the Hospital Setting Staccato® Delivery System Loxapine (ADASUVE®) - Agitation | Phase 4 | Completed | Ferrer Internacional S.A. | 323 | 2016-09-08 | 2020-11-04 |
| Secondary Prevention of Cardiovascular Disease in the Elderly Trial Cardiovascular Polypill, Treatment Prevention for Secondary CV - Myocardial Infarction, Cardiovascular Disease | Phase 3 | Completed | Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III | 2499 | 2016-07-01 | 2025-05-23 |
| Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy Cardiovascular Fixed Dose Combination Pill AAR, Atorvastatin 40 mg, Ramipril 10 mg - Hypertension | Phase 2 | Unknown | Ferrer Internacional S.A. | 528 | 2016-03-01 | 2017-04-10 |
| Changes in Body Composition After EPA Supplementation in Head and Neck Patients EPA supplementation, Placebo - Squamous Cell Carcinoma of Head and Neck | Phase 3 | Completed | Institut Català d'Oncologia | 54 | 2015-12-23 | 2019-09-04 |
| Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo Ozenoxacin, Placebo - Impetigo | Phase 3 | Completed | Ferrer Internacional S.A. | 412 | 2014-06-01 | 2024-08-20 |
| Latin American Pulmonary Hypertension Registry Pulmonary Hypertension | Unknown | Asociacion Latinoamericana de Torax | 500 | 2014-04-01 | 2017-01-24 | |
| Evaluate the Effect of Omega-3 vs Soy Isoflavones in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms Omega-3, Soy Isoflavones - Menopause, Hot Flashes | Phase 4 | Completed | Instituto Palacios | 75 | 2014-03-01 | 2016-09-16 |
| Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo ozenoxacin placebo, retapamulin 1% ointment, ozenoxacin 1% cream - Impetigo | Phase 3 | Completed | Ferrer Internacional S.A. | 465 | 2012-03-01 | 2016-07-01 |
| Single Dose Study to Compare the Pharmacodynamics of Torasemide-PR 10 mg,Torasemide-IR 10 mg and Furosemide-IR 40 mg in Patients With Compensated Heart Failure torasemide-PR, Furosemide-IR, torasemide-IR - Compensated Heart Failure | Phase 4 | Terminated | Ferrer Internacional S.A. | 8 | 2012-02-01 | 2013-04-25 |
| Fixed Dose Combination Drug (Polypill)for Secondary Cardiovascular Prevention. FDC, Separately drugs, simvastatin, aspirin and ramipril - Myocardial Infarction | Phase 3 | Completed | Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III | 2118 | 2012-01-01 | 2014-07-15 |
| Pharmacodynamic Clinical Trial of Cardiovascular Polypill on LDL Cholesterol Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril), Simvastatin, ramipril, acetylsalicylic acid - Elevated LDL Cholesterol | Phase 2 | Terminated | Ferrer Internacional S.A. | 107 | 2010-10-01 | 2013-04-24 |
Showing 20 of 29. Sign in to see all of them.
Amyotrophic Lateral Sclerosis (3) · Hypertension (3) · Candidiasis (2) · Hyperlipoproteinemia Type II (2) · Hypertension, Pulmonary (2) · Impetigo (2) · Myocardial Infarction (2) · Bipolar Disorder (1) · Candidiasis, Vulvovaginal (1) · Cardiovascular Diseases (1) · Cerebral Infarction (1) · Dermatomycoses (1) · Diarrhea (1) · Disease Progression (1) · Emphysema (1)
Ramipril (5) · Aspirin (3) · Blood Circulation (3) · Simvastatin (3) · ozenoxacin (2) · pridopidine (2) · Atorvastatin (1) · Ciclopirox (1) · Control Groups (1) · Cytidine Diphosphate Choline (1) · Docosahexaenoic Acids (1) · Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (1) · Furosemide (1) · Hypolipidemic Agents (1) · ORALIT (1)
Spain (16) · Germany (9) · France (6) · Italy (6) · United States (6) · Poland (5) · Portugal (4) · United Kingdom (4) · Belgium (3) · Netherlands (3) · Argentina (2) · Brazil (2) · Canada (2) · Czechia (2) · Hungary (2)
Antonio Coca, MD, PhD (2) · Valentin Fuster, MD, PhD (2) · Aldiouma Diallo, MS (1) · Alex Roca, MD, PhD (1) · Alexander O Sherenkov, MD, PhD (1) · Alexander V Orlov-Morozov, MD, PhD (1) · Alfonso Castro Beiras, MD, PhD (1) · Andrei Y Baranovsky, MD, PhD (1) · Angel Cano, MD (1) · Angela Felip, MD, PhD (1) · Blas Gil, MD (1) · Boris M Goloschekin, MD, PhD (1) · Carles Brotons, MD, PhD (1) · Carlos Calvo, MD, PhD (1)
PMID 30365584, PMID 19673667, PMID 21906812, PMID 22093195, PMID 22691567, PMID 25193393, PMID 26273191, PMID 29898217, PMID 30282677, PMID 34324628, PMID 36018037, PMID 41013487, PMID 41137739, PMID 41239890
2008 (1), 2009 (1), 2015 (1)